Tsontcho Ianchulev

Dr. Tsontcho Ianchulev

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2014 in Ophthalmology
Verified
Journal Article
Closed access
TITsontcho Ianchulev
Tsontcho Ianchulev
KHKenneth J. Hoffer
Kenneth J. Hoffer
SYSonia H. Yoo
Sonia H. Yoo
DCDavid F. Chang
David F. Chang
MBMichael Breen
Michael Breen
DTDan B. Tran
Dan B. Tran

30 December 2022 in BMJ Open Ophthalmology
Verified
Journal Article
Open access
PDF file
YRYovel Rom
Yovel Rom
RARachelle Aviv
Rachelle Aviv
TITsontcho Ianchulev
Tsontcho Ianchulev
ZDZack Dvey-Aharon
Zack Dvey-Aharon
Aims Diabetic retinopathy (DR) is the most common cause of vision loss in the working age. This research aimed to develop an artificial intelligence (AI) machine learning model which can predict the development of referable DR from fundus imagery of otherwise healthy eyes. Methods Our researchers trained a machine learning algorithm on the EyePACS data set, consisting of 156 363 fundus images. Referrable DR was defined as any level above mild on the International Clinical Diabetic Retinopathy scale. Results The algorithm achieved 0.81 area under receiver operating curve (AUC) when averaging scores from multiple images on the task of predicting development of referrable DR, and 0.76 AUC when using a single image. Conclusion Our results suggest that risk of DR may be predicted from fundus photography alone. Prediction of personalised risk of DR may become key in treatment and contribute to patient compliance across the board, particularly when supported by further prospective research.

18 April 2018 in British Journal of Ophthalmology
Verified
Journal Article
Open access
PDF file
TITsontcho Ianchulev
Tsontcho Ianchulev
DCDavid F Chang
David F Chang
EKEdward Koo
Edward Koo
SMSusan MacDonald
Susan MacDonald
ECErnesto Calvo
Ernesto Calvo
IAIqbal Ike K Ahmed
Iqbal Ike K Ahmed
Aim To assess the safety and efficacy of microinterventional endocapsular nuclear fragmentation in moderate to severe cataracts. Methods This was a prospective single-masked multisurgeon interventional randomised controlled trial (ClinicalTrials.gov NCT02843594) where 101 eyes of 101 subjects with grade 3‒4+ nuclear cataracts were randomised to torsional phacoemulsification alone (controls) or torsional phacoemulsification with adjunctive endocapsular nuclear fragmentation using a manual microinterventional nitinol filament loop device (miLOOP group). Outcome measures were phacoemulsification efficiency as measured by ultrasound energy (cumulative dispersed energy (CDE) units) and fluidics requirements (total irrigation fluid used) as well as incidence of intraoperative and postoperative complications. Results Only high-grade advanced cataracts were enrolled with more than 85% of eyes with baseline best corrected visual acuity (BCVA) of 20/200 or worse in either group. Mean CDE was 53% higher in controls (32.8±24.9 vs 21.4±13.1 with miLOOP assistance) (p=0.004). Endothelial cell loss after surgery was low and similar between groups (7‒8%, p=0.561) One-month BCVA averaged 20/27 Snellen in miLOOP eyes and 20/24 in controls. No direct complications were caused by the miLOOP. In two cases, capsular tears occurred during IOL implantation and in all remaining cases during phacoemulsification, with none occurring during the miLOOP nucleus disassembly part of the procedure. Conclusions Microinterventional endocapsular fragmentation with the manual, disposable miLOOP device achieved consistent, ultrasound-free, full-thickness nucleus disassembly and significantly improved overall phaco efficiency in advanced cataracts. Trial registration number NCT02843594

1 August 2018 in Journal of Cataract & Refractive Surgery
Verified
Journal Article
Closed access
TITsontcho Ianchulev
Tsontcho Ianchulev
DCDavid F. Chang
David F. Chang
EKEdward Koo
Edward Koo
SMSusan MacDonald
Susan MacDonald
We describe a new technique for nucleus disassembly using a microinterventional approach. This is the first report of a microinterventional phacoemulsification-free endocapsular lens fragmentation using a superelastic memory-shaped nickel and titanium (nitinol) microfilament (miLOOP). After standard capsulorhexis and hydrodissection, the microinterventional loop is inserted through the 2.3 mm clear corneal incision. An actuation mechanism is used to unfold the microloop, which glides horizontally on the anterior surface of the lens, expands below the anterior capsule, and then rotates vertically while traveling in the hydrodissection plane to encircle the entire nucleus. Then, the loop is mechanically retracted within the sleeve, achieving full-thickness centripetal segmentation of the nucleus. After rotation of the lens, the loop cuts can be repeated to create 4 or more segments without using phaco energy. The technique is independent of cataract grade and eliminates the need for phacoemulsification or femtosecond energy during the nucleus disassembly step of cataract surgery.

2 January 2023 in British Journal of Ophthalmology
Verified
Journal Article
Open access
PDF file
TITsontcho Ianchulev
Tsontcho Ianchulev
RWRobert N Weinreb
Robert N Weinreb
GKGautam Kamthan
Gautam Kamthan
ECErnesto Calvo
Ernesto Calvo
RPRavinder Pamnani
Ravinder Pamnani
IAIqbal K Ahmed
Iqbal K Ahmed
Background/aims To report a first-in-human trial in open-angle glaucoma (OAG) subjects treated with a new microinterventional biostent-reinforced cyclodialysis technique to enhance supraciliary aqueous drainage. Methods Subjects (N=10; 74.1±7.9 years old) with OAG and cataracts underwent combined phacoemulsification cataract surgery with implantation of a permanent endoscleral supraciliary biostent to reinforce a controlled cyclodialysis cleft. The biostent comprised decellularised scleral allograft tissue microtrephined into a polymer tubular implant intraoperative/postoperative safety, intraocular pressure (IOP) and glaucoma medications were tracked through 12 months postimplantation. Results Baseline medicated IOP averaged 24.2±6.9 mm Hg with subjects using 1.3±0.8 IOP-lowering medications. Successful biostent implantation was achieved in all individuals without significant complications. Immediate IOP lowering was sustained through 1 year. Twelve-month mean IOP was reduced 40% from baseline to 14.6±3.2 mm Hg (p=0.004; paired two-tailed t-test), and 80% of patients achieved >20% IOP reduction. Biostenting reduced glaucoma medication use 62%, from a baseline mean of 1.3 required medications to 0.5 medications (p=0.037) at postoperative 12 months. The biotissue implant was well tolerated and demonstrated good endothelial safety with only 11% endothelial cell loss at 12 months after combined phaco-biostenting surgery, similar to that expected after phacoemulsification alone. Mean BCVA increased from baseline 20/130 Snellen to 20/36 at postoperative 12 months (p=0.001). Conclusion Supraciliary biostenting in OAG patients is well tolerated, has a good safety profile and produces long-term IOP-lowering while reducing glaucoma medication requirements.

1 November 2018 in Clinical Ophthalmology
Verified
Journal Article
Open access
PDF file
LPLouis Pasquale
Louis Pasquale
SLShan Lin
Shan Lin
RWRobert N Weinreb
Robert N Weinreb
JTJames C Tsai
James C Tsai
RKRobert L Kramm
Robert L Kramm
TITsontcho Ianchulev
Tsontcho Ianchulev
Background: Topical high-precision piezo-print delivery of microdoses of latanoprost achieved significant IOP reduction consistent with the eyedropper effect but with a 75% reduced exposure to drugs and preservatives. Prostaglandin analogs are a mainstay glaucoma therapy. However, conventional eyedroppers deliver 30–50 μL drops that greatly exceed the physiologic 7-μL ocular tear film capacity. Eyedropper overdosing floods the eye with excess drug compounds and preservatives, resulting in ocular surface toxicity, periorbitopathy, and other well-characterized ocular side effects. Piezoelectric high-precision microdosing provides targeted delivery that can reduce exposure to both drug and preservatives compared to conventional eyedropper delivery, with the potential to deliver similar biologic effect. Methods: Both eyes (N=60) of 30 healthy volunteers received single 8-μL microdoses of 0.005% latanoprost (0.4 μg; μRx-latanoprost) on the morning of Days 1 and 2 using a high-precision, piezo-print horizontal delivery system. Diurnal IOP was measured before and 2 days after microdosing. Main efficacy outcomes were diurnal IOP change after μRx-latanoprost microdosing and accurate microdosing success rates, and the primary safety outcome was adverse event (AE) incidence. Results: μRx-latanoprost reduced baseline IOP by 26% and 30% at 1 and 2 days postadministration, respectively. Successful topical dosing was achieved in 100% of technician-assisted deliveries. All patients successfully self-administered microdoses after receiving training. Microdose administration was well tolerated and did not result in any AEs. Conclusion: Microdosing of 0.4 μg of μRx-latanoprost achieved significant IOP reduction. Lower ocular exposure with topical prostaglandin analog microdosing can enable new therapeutic opportunities for optimizing glaucoma treatment. Microdosing may also be beneficial in reducing ocular side effects associated with excessive drug product and preservatives often used to treat chronic ocular diseases such as glaucoma.